PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : M

Records returned : 151 (on 17 May 2024 at 08:58:15).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Macitentan
No Information Returned
Macrogol 3350
No Information Returned
Macrogol 4000
No Information Returned
Mafenide
No Information Returned
Magnesium aspartate
No Information Returned
Magnesium carbonate
No Information Returned
Magnesium chloride
No Information Returned
Magnesium citrate
No Information Returned
Magnesium glycerophosphate
No Information Returned
Magnesium hydroxide
No Information Returned
Magnesium lactate
No Information Returned
Magnesium orotate
No Information Returned
Magnesium oxide
No Information Returned
Magnesium sulfate
No Information Returned
Magnesium sulphate
No Information Returned
Magnesium trisilicate
No Information Returned
Malathion
No Information Returned
Maltodextrin
No Information Returned
Mandelic acid
No Information Returned
Mannitol
No Information Returned
Maprotiline hydrochloride
No Information Returned
Maraviroc
No Information Returned
Mazindol
No Information Returned
Measles, mumps and rubella vaccine
No Information Returned
Mebendazole
No Information Returned
Mebeverine hydrochloride
No Information Returned
Mebeverine hydrochloride compound preparations
No Information Returned
Mecasermin
No Information Returned
Meclozine hydrochloride
No Information Returned
Mecobalamin
No Information Returned
Mecysteine hydrochloride
No Information Returned
Medicated stockings
No Information Returned
06.04.01
Medroxyprogesterone acetate
Transgender Health - adults
Amber
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
10.01.01
Mefenamic acid
Dysmenorrhoea
Green
Formulations :
  • Capsules
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
10.01.01
Mefenamic acid
Menorrhagia
Green
Formulations :
  • Capsules
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
10.01.01
Mefenamic acid
Dysmenorrhoea
Non Formulary
Formulations :
  • Oral suspension
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Consider alternative therapy if a liquid formulation is required.
10.01.01
Mefenamic acid
Menorrhagia
Non Formulary
Formulations :
  • Oral suspension
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Consider alternative therapy if a liquid formulation is required.
10.01.01
Mefenamic acid
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
See separate entry for use in menorrhagia and dysmenorrhoea.
Mefloquine hydrochloride
No Information Returned
Megestrol acetate
No Information Returned
04.01.01
Melatonin
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Rapid eye movement disorder.
Generic 2mg MR tablets.
04.01.01
Melatonin
Jet lag disorder
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
10.01.01
Meloxicam
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Not a preferred NSAID, limited place in therapy. ASPH - rheumatology only.
Melperone hydrochloride
No Information Returned
Melphalan
No Information Returned
04.11.00
Memantine hydrochloride
Multiple sclerosis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Menadiol sodium phosphate
No Information Returned
Meningococcal A + C + W135 + Y vaccine
No Information Returned
Meningococcal A + C vaccine
No Information Returned
Meningococcal B vaccine
No Information Returned
Meningococcal C vaccine
No Information Returned
Menotrophin
No Information Returned
Menthol
No Information Returned
Mepacrine hydrochloride
No Information Returned
Mepenzolate bromide
No Information Returned
Mepivacaine hydrochloride
No Information Returned
Mepolizumab
No Information Returned
Meprobamate
No Information Returned
04.07.02
Meptazinol
Pain (non-malignant)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
04.07.02
Meptazinol hydrochloride
Pain
Red
Formulations :
  • Injection
  • Intramuscular injection (IM)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Obstetric analgesia
Mepyramine maleate
No Information Returned
Mercaptamine
No Information Returned
Mercaptamine hydrochloride
No Information Returned
08.01.03
08.02.01
Mercaptopurine
Inflammatory bowel disease
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
08.01.03
08.02.01
Mercaptopurine
Neurology indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
08.01.03
08.02.01
Mercaptopurine
Hepatology Indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
Meropenem
No Information Returned
01.05.01
Mesalazine
Inflammatory bowel disease
Green
Formulations :
  • Gastro-resistant tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Prescribe by brand
Gastro-resistant tablets = Octasa or Salofalk are 1st line for new patients Asacol tablets are non-formulary
01.05.01
Mesalazine
Inflammatory bowel disease
Green
Formulations :
  • Suppositories
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by brand
Octasa, Salofalk, Pentasa
01.05.01
Mesalazine
Inflammatory bowel disease
Green
Formulations :
  • Enema
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by brand
Pentasa / Salofalk enema
01.05.01
Mesalazine
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
R
Important
Prescribe by brand
Mezevant XL Reserve for patients with a high pill burden.
01.05.01
Mesalazine
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Granules (slow release)
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by brand
Pentasa modified-release tablets and granules for patients who require upper GI release.
Mesalazine (Systemic)
No Information Returned
Mesna
No Information Returned
Mesterolone
No Information Returned
Mesuximide
No Information Returned
Metaraminol
No Information Returned
Metformin hydrochloride
No Information Returned
Metformin hydrochloride/pioglitazone
No Information Returned
Metformin hydrochloride/rosiglitazone
No Information Returned
Metformin hydrochloride/sitagliptin
No Information Returned
Metformin hydrochloride/vildagliptin
No Information Returned
Methadone hydrochloride
No Information Returned
05.01.13
Methenamine hippurate
Urinary Tract Infection (UTIs)
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Methionine
No Information Returned
Methocarbamol
No Information Returned
01.05.03
10.01.03
13.05.03
Methotrexate
Rheumatology indications
Amber
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
WEEKLY dosing.
01.05.03
10.01.03
13.05.03
Methotrexate
Rheumatology indications
Amber
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
WEEKLY dosing.
2.5mg tablets ONLY. DO NOT PRESCRIBE OR SUPPLY 10mg tablets
01.05.03
10.01.03
13.05.03
Methotrexate
Respiratory disease indications
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
WEEKLY dosing. Only 2.5mg tablets to be prescribed. DO NOT prescribe or supply 10mg tablets
01.05.03
10.01.03
13.05.03
Methotrexate
Dermatology indications
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Weekly dosing. Tablets - only to prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets
01.05.03
10.01.03
13.05.03
Methotrexate
Neurology indications
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets. WEEKLY dosing.
01.05.03
10.01.03
13.05.03
Methotrexate
Uveitis
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
WEEKLY dosing. Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets.
01.05.03
10.01.03
13.05.03
Methotrexate
Scleritis
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
WEEKLY dosing. Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets.
01.05.03
10.01.03
13.05.03
Methotrexate
Gastroenterology indications
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
WEEKLY dosing. Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets.
Methoxamine hydrochloride
No Information Returned
Methoxsalen
No Information Returned
Methoxy polyethylene glycol-epoetin beta
No Information Returned
Methyl nicotinate
No Information Returned
Methyl salicylate
No Information Returned
Methyl salicylate/levomenthol
No Information Returned
Methyl-5-aminolevulinate
No Information Returned
Methylcellulose
No Information Returned
Methyldopa
No Information Returned
01.06.06
Methylnaltrexone bromide
Constipation
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
For opioid-induced constipation in terminally ill patients when response to other laxatives is inadequate
RSCH Palliative Care Team only
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
Prescribe by brand. Xaggitin XL, Xenidate XL and Delomsart are the locally agreed brands.
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Immediate release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
Prescribe immediate release tablets generically
Methylprednisolone
No Information Returned
Methylprednisolone aceponate
No Information Returned
10.01.02
Methylprednisolone acetate
Soft tissue and joint disorders
Green
Formulations :
  • Intra-articular injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Methylprednisolone sodium succinate
No Information Returned
10.01.02
Methylprednisolone with lidocaine
Soft tissue and joint disorders
Green
Formulations :
  • Intra-articular injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Methyltestosterone
No Information Returned
Methysergide
No Information Returned
Metipranolol
No Information Returned
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Un
Important
2nd line treatment option. Should not be prescribed for longer than 5 days.
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Un
Important
2nd line treatment option. Should not be prescribed for longer than 5 days.
An option in patients with swallowing difficulties.
Metolazone
No Information Returned
Metoprolol tartrate
No Information Returned
Metoprolol tartrate with diuretic
No Information Returned
Metreleptin
No Information Returned
07.02.02
13.10.01
Metronidazole
Bacterial vaginosis
Green
Formulations :
  • Vaginal gel
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Refer to local antimicrobial guidelines. Oral metronidazole is as effective as topical treatment and is more cost-effective.
07.02.02
13.10.01
Metronidazole
Bacterial vaginosis
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Refer to local antimicrobial guidelines. Oral metronidazole is as effective as topical treatment and is more cost-effective.
Metyrapone
No Information Returned
02.03.02
10.02.02
Mexiletine hydrochloride
Myotonia
Red
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NHSE
BlueTeq
NICE
Mianserin hydrochloride
No Information Returned
Micafungin
No Information Returned
Miconazole
No Information Returned
Miconazole nitrate
No Information Returned
Midazolam hydrochloride
No Information Returned
04.08.02
Midazolam hydrochloride (Buccolam)
Status epilepticus
Blue
Formulations :
  • Pre-filled oral syringe
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
CD
SA
NICE
Important
Preferred
Prescribe by BRAND. Buccolam is currently the preferred, lower-cost in patients over 3 months of age
04.08.02
Midazolam hydrochloride (Buccolam)
Status epilepticus
Red
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Un
Important
Unlicensed preparations / specials have a Red traffic light status - not for prescribing in primary care.
04.08.02
Midazolam hydrochloride (Buccolam)
Status epilepticus
Red
Formulations :
  • Liquid
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
R
U
Important
ASPH Paediatrics only - (high-cost) unlicensed midazolam liquid 12.5mg/5ml sugar free.
Midazolam maleate
No Information Returned
04.08.02
Midazolam maleate (Epistatus)
Status epilepticus
Blue
Formulations :
  • Pre-filled oral syringe
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
CD
SA
NICE
Important
Prescribe by BRAND (Epistatus). However, Buccolam is currently the preferred, lower-cost in patients over 3 months of age
04.08.02
Midazolam maleate (Epistatus)
Status epilepticus
Red
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Un
Important
Unlicensed preparations / specials have a Red traffic light status - not for prescribing in primary care.
04.08.02
Midazolam maleate (Epistatus)
Status epilepticus
Red
Formulations :
  • Liquid
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
R
U
Important
ASPH Paediatrics only - (high-cost) unlicensed midazolam liquid 12.5mg/5ml sugar free.
Midodrine hydrochloride
No Information Returned
Midostaurin
No Information Returned
07.01.02
Mifepristone
Termination of pregnancy
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
R
Important
Restricted to use by Gynaecology and Obstetrics departments only
Mifepristone/misoprostol
No Information Returned
Migalastat
No Information Returned
Miglustat
No Information Returned
04.07.04
Migraleve
Migraine (acute)
Non Formulary
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Milrinone lactate
No Information Returned
Minocycline hydrochloride
No Information Returned
Minoxidil
No Information Returned
07.04.02
Mirabegron
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Solifenacin is 1st line. Mirabegron for use when antimuscarinics are contraindicated, patients with CNS adverse effects or patients requiring a more potent treatment.
Mirtazapine
No Information Returned
01.03.04
07.01.01
Misoprostol
Termination of pregnancy
Red
Formulations :
  • Vaginal tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
R
Important
Restricted to use by Gynaecology and Obstetrics departments only
Misoprostol (Gynaecology)
No Information Returned
Mitomycin
No Information Returned
Mitotane
No Information Returned
Mitoxantrone
No Information Returned
Mivacurium chloride
No Information Returned
03.04.01
Mizolastine
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Moclobemide
No Information Returned
04.04.00
Modafinil
Narcolepsy
Amber
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy safety warnings.
04.04.00
Modafinil
Multiple sclerosis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Safety in pregnancy warnings.
04.04.00
Modafinil
Shift work sleep disorder
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Pregnancy safety warnings.
04.04.00
Modafinil
Sleep apnoea
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Pregnancy safety warnings.
04.04.00
Modafinil
Hypersomnia
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Pregnancy safety warnings.
Moexipril hydrochloride
No Information Returned
Molgramostim
No Information Returned
Molnupiravir
No Information Returned
Mometasone furoate
No Information Returned
Mometasone furoate/olopatadine hydrochloride
No Information Returned
Mometasone/glycopyrronium/indacaterol
No Information Returned
Monobasic potassium phosphate
No Information Returned
Montelukast
No Information Returned
Morphine hydrochloride
No Information Returned
01.04.02
04.07.02
Morphine (Opium Tincture)
Diarrhoea
N/A
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD2
CD
04.07.02
Morphine sulfate
Pain (non-malignant)
Green
Formulations :
  • Modified release capsules
  • Modified release tablets
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands
04.07.02
Morphine sulfate
Pain (non-malignant)
Red
Formulations :
  • Injection
  • Solution for infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Morphine tartrate and cyclizine tartrate
No Information Returned
Moxifloxacin
No Information Returned
Moxifloxacin hydrochloride
No Information Returned
Moxisylyte hydrochloride
No Information Returned
Moxonidine
No Information Returned
Mupirocin
No Information Returned
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Rheumatology indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Uveitis
Amber
Formulations :
  • Capsules
  • Gastro-resistant tablets
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Scleritis
Amber
Formulations :
  • Capsules
  • Gastro-resistant tablets
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Gastroenterology indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Haematology Indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Hepatology Indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Oral disease indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Renal indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Respiratory disease indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Dermatology indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Neurology indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
Mycophenolic sodium
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More